PXD101

• CAT Number: A000593
• CAS Number: 414864-00-9
• Molecular Formula: C15H14N2O4S
• Molecular Weight: 318.347
• Purity: ≥95%
• Synonyms: NSC726630, PX-105684; PXD101
• Target: HDAC
• Solubility: >15.9mg/mL in DMSO
• IUPAC Name: (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
• InChI: InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
• InChIKey: NCNRHFGMJRPRSK-MDZDMXLPSA-N
• SMILES: C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO

PXD101, also known as Belinostat, is a potent HDAC inhibitor used in advanced cancer research and treatment. This compound plays a crucial role in studying epigenetic modifications, cell cycle regulation, and apoptosis in cancer cells. Its application in clinical trials and drug development highlights its potential in treating various malignancies, including lymphoma and solid tumors. Ideal for oncology research, PXD101 enhances the understanding of histone deacetylase inhibition and its therapeutic implications, making it indispensable for innovative cancer treatment strategies.

Reference

1: Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M. Activity of
the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of
prostate cancer. Int J Cancer. 2008 Mar 15;122(6):1400-10. PubMed PMID: 18027850.

2: Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg
M, Jensen PB, Sehested M, Ritchie JW. The histone deacetylase inhibitor PXD101
synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and
in vivo. Cancer Chemother Pharmacol. 2007 Jul;60(2):275-83. Epub 2006 Nov 24.
PubMed PMID: 17124594.

3: Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M,
Lichenstein HS, Jeffers M. Activity of PXD101, a histone deacetylase inhibitor,
in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95.
PubMed PMID: 16928830.

4: Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue
NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor
xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther.
2003 Aug;2(8):721-8. PubMed PMID: 12939461.